Free Trial
NASDAQ:SNES

Senestech Q1 2026 Earnings Report

Senestech logo
$1.63 -0.10 (-5.78%)
As of 10:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Senestech EPS Results

Actual EPS
N/A
Consensus EPS
-$0.33
Beat/Miss
N/A
One Year Ago EPS
N/A

Senestech Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.63 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Senestech Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
5:00PM ET

Conference Call Resources

Senestech Earnings Headlines

Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
See More Senestech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senestech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senestech and other key companies, straight to your email.

About Senestech

Senestech (NASDAQ:SNES) (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company’s core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.

The company’s flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction. Administered through tamper-resistant bait stations, ContraPest delivers a proprietary formulation designed to lower fertility in target populations of Norway rats and roof rats. SenesTech complements its product offering with consultation and support services, assisting customers in designing monitoring programs, interpreting data, and implementing integrated pest management strategies tailored to municipal, commercial, and industrial settings.

Founded in 2001 and headquartered in Prescott, Arizona, SenesTech secured EPA approval for ContraPest in 2016, marking a milestone as the first fertility control agent for rodents available on the market. Since then, the company has expanded its distribution network across North America, serving food processing facilities, hospitality venues, healthcare institutions, warehouses, and municipal vector control agencies. SenesTech continues to pursue research and development of next-generation fertility control technologies and to explore potential applications in emerging global pest and wildlife management markets.

Led by an executive team with backgrounds in biotechnology, environmental science, and pest management, SenesTech is governed by a board of directors comprising industry experts in commercial product development and regulatory affairs. The company’s management structure supports ongoing collaboration with regulatory agencies and commercial partners to advance innovative solutions that address public health and sustainability concerns associated with rodent infestations.

View Senestech Profile